Our reporters bring you news and highlights from BIO’s in-person and virtual events.
Industry leaders at BIO 2026 discussed the proposed PDUFA VIII next steps. After a year of discussion with the industry and 127 meetings with […]
BIO 2026: Industry PDUFA negotiators describe their agreement with FDA Read More »
Experts at the BIO International Convention examine the growth of the 340B drug pricing program, duplicate discounts, patient access, and calls for greater transparency.
BIO 2026: 340B faces growing calls for transparency, patient-focused reform Read More »
From sickle cell disease to multiple sclerosis and childhood leukemia, patients and advocates reflected on becoming pioneers in therapies that are changing medicine.
BIO 2026: ‘I am alive today because of biotech’ Read More »
At a time when U.S. biotech leadership is being challenged, the patent system that enables life-saving innovations is beset by a toxic stew of
BIO 2026: Biotech threatened by pressures on patent protection Read More »
Industry and government leaders at BIO 2026 said stronger biotechnology policy, regulatory modernization, and public-private partnerships are essential to maintaining U.S. leadership in biotech
BIO 2026: American biotech leadership protects patients and national security Read More »
What started as a conversation, in a bar, written on a napkin in 1976, between biochemist Dr. Herbert W. Boyer and investor Robert A.
After 50 years of biotech, can AI help answer the next impossible question? Read More »
What will it take to build a stronger, more resilient U.S. life sciences industry? In a June 23 fireside chat at the 2026 BIO
BIO 2026: Gov. Tina Kotek on Oregon’s thriving bioscience sector Read More »
Gary Sinise, Marcus Freeman, and BIO President & CEO John F. Crowley discussed leadership, resilience, and purpose at BIO 2026, drawing lessons from military
BIO 2026: Gary Sinise, Marcus Freeman on leadership, service, and resilience Read More »
Industry, academic, and policy leaders at BIO 2026 discussed how federal research funding, private investment, and public-private partnerships can strengthen the U.S. biopharma ecosystem
The new BIO-Norstella State of Emerging Biotech report finds venture capital has returned, pipelines are becoming more efficient, and emerging biotech companies continue to
BIO 2026: As capital returns, focus on quality over quantity Read More »
